New study tests Anti-Inflammatory drug for Crohn's in china
NCT ID NCT07663526
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will test the drug Tabellvi (adalimumab) in 50 Chinese adults with moderate to severe Crohn's disease. The goal is to see how safe and effective it is in real-world settings, focusing on side effects and whether patients achieve remission after 26 weeks. Participants must have failed other treatments like steroids or immunosuppressants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Adalimumab (Tabellvi), a drug that blocks inflammation
What this could lead to
If successful, this could confirm that adalimumab works well and safely for Chinese patients with Crohn's disease in everyday medical practice.
What could go wrong
This is a small, single-arm study with no comparison group, so results may not be definitive. Side effects like infections or allergic reactions are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fuyang People's Hospital
Fuyang, Anhui, 236000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Huai'an First People's Hospital
Huaian, Jiangsu, 223001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Meihekou Central Hospital
Meihekou, Jilin, 135022, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai Jiao Tong University School of Medicine, Renji Hospital
Shanghai, Shanghai Municipality, 200001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Second Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450014, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yancheng No.1 People's Hospital
Yancheng, Jiangsu, 224500, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhoukou Central Hospital
Zhoukou, Henan, 466000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••